Cargando…

A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma

BACKGROUND: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). This current pilot study assessed the feasibility of sequential induction therapy in patients with stage IIB to IIIA NSCLC adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Chao, Ma, Yuanyuan, Feng, Qin, Fang, Fang, Bai, Hua, Zhao, Bingtian, Yan, Shi, Wu, Nan, Zheng, Qingfeng, Li, Shaolei, Chen, Jinfeng, Wang, Jia, Feng, Yuan, Wang, Yuzhao, Pei, Yuquan, Fang, Jian, Yang, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643858/ https://www.ncbi.nlm.nih.gov/pubmed/23621919 http://dx.doi.org/10.1186/1477-7819-11-96

Ejemplares similares

A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer
por: Lv, Chao, et al.
Publicado: (2013)

Implications of False Negative and False Positive Diagnosis in Lymph Node Staging of NSCLC by Means of (18)F-FDG PET/CT
por: Li, Shaolei, et al.
Publicado: (2013)

Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
por: Rajan, Narayan, et al.
Publicado: (2014)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Glycoprotein IIb/IIIa and P2Y(12) Induction by Oligochitosan Accelerates Platelet Aggregation
por: Periayah, Mercy Halleluyah, et al.
Publicado: (2014)

Absence of platelet membrane glycoproteins IIb/IIIa from monocytes
Publicado: (1985)

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
por: Kaluski, Edo
Publicado: (2008)

Receptor GP IIb/IIIa as an Indicator of Risk in Vascular Events
por: Fiodorenko-Dumas, Żanna, et al.
Publicado: (2019)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
por: Liu, Yu-Tao, et al.
Publicado: (2020)

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
por: Suwaidi, Jassim Al, et al.
Publicado: (2001)

The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma
por: Kim, Seo-Hee, et al.
Publicado: (2021)

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2019)

Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
por: Iannetta, Loredana, et al.
Publicado: (2013)

Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer
por: Li, Hongbo, et al.
Publicado: (2020)

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer
por: Palka, Magda, et al.
Publicado: (2017)

Effect of Platelet Glycoprotein IIb/IIIa PLA2 Polymorphism on Severity of Pulmonary Thromboembolism
por: Boroujeni, Hamid Rouhi, et al.
Publicado: (2014)

Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
por: Hekmat, Hamidreza, et al.
Publicado: (2022)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?
por: Zheng, Wei, et al.
Publicado: (2015)

Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins
Publicado: (1990)

Thrombin-induced platelet membrane glycoprotein IIb and IIIa complex formation. An electron microscope study
Publicado: (1981)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
por: Choi, Woong Gil, et al.
Publicado: (2011)

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant
por: Deng, Qiao, et al.
Publicado: (2020)

Detection of High-Risk Atherosclerotic Plaques with Ultrasound Molecular Imaging of Glycoprotein IIb/IIIa Receptor on Activated Platelets
por: Guo, Shengcun, et al.
Publicado: (2015)

Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity
Publicado: (1993)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

Testicular orphan nuclear receptor 4-associated protein 16 promotes non-small cell lung carcinoma by activating estrogen receptor β and blocking testicular orphan nuclear receptor 2
por: FANG, FANG, et al.
Publicado: (2012)

A prospective analysis of complications related to the use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
por: Rocha, RM, et al.
Publicado: (2001)

Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke
por: Lee, John-Ih, et al.
Publicado: (2017)

Influence of glycoprotein IIb/IIIa inhibitors on bleeding events after successful resuscitation and percutaneous coronary intervention
por: Biever, Paul Marc, et al.
Publicado: (2019)

Relationship of Platelet Glycoprotein IIb/IIIa and CD62P With Hypercoagulable State After Oncologic Surgery
por: Zhong, Xin, et al.
Publicado: (2020)

The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma
por: Li, Xiao‐Min, et al.
Publicado: (2022)

Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
por: Lv, C., et al.
Publicado: (2023)

A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy
por: ZHENG, XIAO, et al.
Publicado: (2014)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9fknrmg514159i8t8b49f14iue